Alfonso Diaz

Dr. Alfonso Diaz

PHARMACY, Benemérita Universidad Autonoma de Puebla, Puebla, Mexico
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2018 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
STSamuel Trevino
Samuel Trevino
ADAlfonso Diaz
Alfonso Diaz
ESEduardo Sánchez-Lara
Eduardo Sánchez-Lara
BSBrenda L. Sanchez-Gaytan
Brenda L. Sanchez-Gaytan
JPJose Manuel Perez-Aguilar
Jose Manuel Perez-Aguilar
EGEnrique González-Vergara
Enrique González-Vergara
Vanadium compounds have been primarily investigated as potential therapeutic agents for the treatment of various major health issues, including cancer, atherosclerosis, and diabetes. The translation of vanadium-based compounds into clinical trials and ultimately into disease treatments remains hampered by the absence of a basic pharmacological and metabolic comprehension of such compounds. In this review, we examine the development of vanadium-containing compounds in biological systems regarding the role of the physiological environment, dosage, intracellular interactions, metabolic transformations, modulation of signaling pathways, toxicology, and transport and tissue distribution as well as therapeutic implications. From our point of view, the toxicological and pharmacological aspects in animal models and humans are not understood completely, and thus, we introduced them in a physiological environment and dosage context. Different transport proteins in blood plasma and mechanistic transport determinants are discussed. Furthermore, an overview of different vanadium species and the role of physiological factors (i.e., pH, redox conditions, concentration, and so on) are considered. Mechanistic specifications about different signaling pathways are discussed, particularly the phosphatases and kinases that are modulated dynamically by vanadium compounds because until now, the focus only has been on protein tyrosine phosphatase 1B as a vanadium target. Particular emphasis is laid on the therapeutic ability of vanadium-based compounds and their role for the treatment of diabetes mellitus, specifically on that of vanadate- and polioxovanadate-containing compounds. We aim at shedding light on the prevailing gaps between primary scientific data and information from animal models and human studies.

26 June 2017 in Synapse
Verified
Journal Article
Closed access
PDF file
EREduardo Rojas-Gutierrez
Eduardo Rojas-Gutierrez
GMGuadalupe Muñoz-Arenas
Guadalupe Muñoz-Arenas
STSamuel Treviño
Samuel Treviño
BEBlanca Espinosa
Blanca Espinosa
RCRaúl Chavez
Raúl Chavez
JGJorge Guevara
Jorge Guevara

1 April 2009 in Neuroscience Letters
Verified
Journal Article
Closed access
ILIlhuicamina Daniel Limón
Ilhuicamina Daniel Limón
LMLiliana Mendieta
Liliana Mendieta
ADAlfonso Diaz
Alfonso Diaz
GCGermán Chamorro-Cevallos
Germán Chamorro-Cevallos
BEBlanca Espinosa
Blanca Espinosa
JGJorge Guevara
Jorge Guevara

1 July 2020 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
STSamuel Trevino
Samuel Trevino
ADAlfonso Diaz
Alfonso Diaz

13 June 2015 in Synapse
Verified
Journal Article
Closed access
PDF file
STSamuel Trevino
Samuel Trevino
PAPatrícia Aguilar‐Alonso
Patrícia Aguilar‐Alonso
JHJose Angel Flores Hernandez
Jose Angel Flores Hernandez
EBEduardo Brambila
Eduardo Brambila
JGJorge Guevara
Jorge Guevara
ADAlfonso Diaz
Alfonso Diaz

1 March 2016 in Behavioural Brain Research
Verified
Journal Article
Closed access
GFGonzalo Flores
Gonzalo Flores
JMJulio César Morales-Medina
Julio César Morales-Medina
ADAlfonso Diaz
Alfonso Diaz